

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 June 2009 (25.06.2009)

PCT

(10) International Publication Number
WO 2009/077769 A2

(51) International Patent Classification:
A61K 9/00 (2006.01) A61B 5/00 (2006.01)
A61K 47/22 (2006.01)

(74) Agent: WALLIS, Naomi, Rachel; Withers & Rogers LLP,
Goldings House, 2 Hays Lane, London SE1 2HW (GB).

(21) International Application Number:
PCT/GB2008/004233

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:
19 December 2008 (19.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0724772.9 19 December 2007 (19.12.2007) GB

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


(71) Applicant (for all designated States except US): UCL BUSINESS PLC [GB/GB]; The Network Building, 97 Tottenham Court Road, London W1T 4TP (GB).

Published:

— without international search report and to be republished upon receipt of that report

(54) Title: CARRIER

Figure 1



WO 2009/077769 A2

(57) Abstract: The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.

Carrier

5 The invention relates to the use of Vitamin E derivatives such as tocopherol, its derivatives and related molecules, as a carrier for the delivery of pharmaceutical or other agents to the retina, particularly when delivered topically.

10 The delivery of molecules to the posterior region of the eye from topical dosing has been a goal set by many ocular pharmacologists. It has become increasingly popular with the advent of anti-VEGF therapies for age-related macular degeneration and diabetic retinopathy.

15 Typically topical ocular drug administration is accomplished by eye drops, but they have only a short contact time on the eye surface. Following eye drop administration the peak concentration of agents in the anterior chamber is commonly reached after 20–30 min, and is typically two orders of magnitude lower than that applied. From the aqueous humor the agent has an easy access to the iris, ciliary body, lens and retina. Some part of topically administered drugs may absorb across the bulbar conjunctiva to the sclera and further to the uvea and posterior segment. The passage of agents through the cornea is a non-invasive method for allowing drugs to pass into the posterior segment. The corneal route of delivery is useful not only for therapies but also diagnostic methodologies.

20 It is of particular interest to be able to deliver cell death markers to the posterior region of the eye and especially to the retina in order to monitor cell death associated with degenerative diseases such as glaucoma. Previously, it has been necessary to deliver cell death markers, such as annexins, intra-vitreously or intra-venously.

25 The inventors have surprisingly found that Vitamin E derivatives, especially tocopherols may be used as carriers, to enhance the delivery of agents such as annexins to the posterior region of the eye following topical application.

According to the invention there is provided a pharmaceutical composition comprising a Vitamin E derivative and a cell death marker.

30 Also provided is the use of a Vitamin E derivative as a carrier to deliver an agent to the posterior segment of the eye.

Further provided is a method of delivery of an agent to the posterior region of the eye, comprising administering the agent topically to the eye, in combination with a Vitamin E derivative.

5 The term Vitamin E derivative is used herein to refer to a tocol or tocotrienol derivative with similar biological activity to α -tocopherol. In particular, the term refers to tocopherols and tocotrienols. There are 8 Vitamin E isomeric molecules: the four tocopherols possess a 4',8',12'-trimethyltridecyl phytol side chain and the four tocotrienols differ by the presence of double bonds at the 3',7' and 11' positions of the side chain. The term also encompasses
10 molecules that are derivatives of tocopherols and tocotrienols, or which are variants of those molecules, having slightly different structures but which have similar functionality.

Vitamin E is comprised of two homologous series of tocochromanols, termed "tocopherols" and "tocotrienols." In particular, a tocopherol is a mono, di or tri-methyltocol, which may
15 have vitamin E activity. The term is well known in the art. Also included in the definition of tocopherol intended herein are derivatives of tocopherol, particularly functional derivatives, that is to say those that retain the carrier function of the parent molecule. An example of a tocopherol derivative is TPGS (D- α -tocopherylsuccinate esterified to polyethyleneglycol 1000). A tocotrienol is a tocol with three double bonds in the side chain, i.e., with three
20 additional double bonds in the phytol chain, thus a 6-(3',7',11',15'-tetramethyl-2',6',10',14'-hexadecatetraenyl)-1,4-hydroquinone or a 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl) chroman-6-ol. The natural products carry methyls at one or more of positions 5, 7, and 8 of
25 the chromanol and are thus identical, except for the unsaturation in the phytol-like side chain, to the tocopherols; also analogous is the cyclization to form a chromanol derivative and oxidation to form the tocotrienolquinones (or chromenols). Tocotrienol terminology is used to indicate relationships to tocols and tocoenols (vitamin E-like), the chromanol terminology to indicate relationship to the isoprenoidal compounds of the vitamin K and coenzyme Q series.

30

The term 'cell death marker' refers to a marker that allows live cells to be distinguished from cells that are dying or have died. For example it may be a compound or molecule that specifically binds to live cells but not to dead or dying cells, or that specifically binds to dead

or dying cells but not to live cells. Cell death markers include, for example the annexin family of proteins. Annexins are proteins that bind reversibly to cellular membranes in the presence of cations. Annexins useful in the invention may be natural or may be recombinant. The protein may be whole or maybe a functional fragment, that is to say a fragment or region 5 of an annexin that binds specifically to the same molecules as the whole protein. Also included are functional derivatives of such proteins. In particular, the term is considered to encompass molecules containing an “annexin repeat”, that is a domain of approximately 70 amino-acids that is conserved both within individual annexins and also between members of the family. A variety of annexins are available, such as those described in US Patent 10 Application Publication No. 2006/0134001A. A preferred annexin is annexin V, which is well known in the art. Other annexins include 2, 6 and 11. Other markers of cell death, especially apoptosis are known in the art, including for example the C2A domain of synaptotagmin (Jung *et al.*, *Bioconging Chem.* 2004 Sep-Oct; 15(5): 983-7) and propidium iodide.

15

The cell death marker may be labelled with a fluorescent or other visible or identifiable label. For example, the cell death marker may be labelled with an infrared or near infrared label, in particular an infrared dye. The cell death marker may be labelled using standard techniques.

20 The term posterior segment of the eye refers to structures at the rear of the eye including, for example the lens, trabecular meshwork, uvea (including the ciliary body), vitreous and retina. In particular, the invention allows improved delivery to the retina.

25 Tocopherols may also be used in the administration of other active agents and pharmaceuticals, such as neuroprotectants (such as Memantine), growth factors and growth factor-antagonists (including anti-angiogenic molecules), antibodies (such as Lucentis and Avastin), aptamers (such as Macugen), steroids (such as Triamcinolone), molecular agents.

30 The composition of the invention may also include at least one of phosphatidylserine (or similar molecule such as phosphatidylethanolamine) and cholesterol or derivative thereof, such as an oxysterol.

The compositions of the invention may be used to deliver other molecules, agents or compositions to the posterior region of the eye. Accordingly, the composition may

additionally contain one or more agents to be delivered. Such agents may include therapeutically or biologically active agents, for example.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Methods to accomplish the administration are known to those of ordinary skill in the art. For example, the administration may be intravenous, intraperitoneal, intramuscular, intravitreous, intracavity, subcutaneous or topical.

Solutions or suspensions used for intradermal or subcutaneous application typically include at least one of the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycol, glycerine, propylene glycol, or other synthetic solvent; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetate, citrate, or phosphate; and tonicity agents such as sodium chloride or dextrose. The pH can be adjusted with acids or bases. Such preparations may be enclosed in ampoules, disposable syringes, or multiple dose vials.

Solutions or suspensions used for intravenous or intravitreous administration may include a carrier such as physiological saline, bacteriostatic water, CremophorELT[™] (BASF, Parsippany, NJ), ethanol, or polyol. In all cases, the composition must be sterile and fluid for easy syringability. Proper fluidity can often be obtained using lecithin or surfactants. The composition must also be stable under the conditions of manufacture and storage. Prevention of microorganisms can be achieved with antibacterial and antifungal agents, e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, isotonic agents (sugar), polyalcohols (mannitol and sorbitol), or sodium chloride may be included in the composition. Prolonged absorption of the composition can be accomplished by adding an agent which delays absorption, e.g., aluminium monostearate and gelatin.

The pharmaceutical composition according to the invention is preferably for topical administration, that is to say, preferably for application to the surface of the eyeball, in the form of eye drops or other topical form. Accordingly, the pharmaceutical composition may additionally contain other carriers, vehicles or excipients such as sodium chloride, benzalkonium chloride, sodium dihydrogen phosphate monohydrate, anhydrous disodium phosphate, and water for injections.

Also provided is the use of a Vitamin E derivative as a carrier for the delivery of at least one agent to the posterior region of the eye. The Vitamin E derivative may be used in conjunction with a cell death marker, for example pharmaceutical compositions as discussed above may 5 be used as the carrier. The carrier may be used to deliver therapeutic, diagnostic or other agents to retina and surrounding areas. Methods for delivering such agents are also provided.

The invention will now be described in detail by way of example only, with reference to the figures in which:

10 Figure 1 is a DARC image of a rat retina taken 30 minutes after treatment with topical annexin V after induction of apoptosis by treatment with intravitreal staurosporine (SSP). The image shows clearly that the infrared annexin V can be detected in the retina, labelling the retinal ganglion cell apoptosis induced by SSP.

15 Figure 2a is a DARC image of a rat retina taken 2 hours after treatment with topical annexin V after induction of apoptosis by treatment with intravitreal staurosporine (SSP). The image shows clearly that the infrared annexin V can be detected in the retina, labelling the retinal ganglion cell apoptosis induced by SSP. Figure 2b is the associated histological image.

20 Figure 3 shows examples of a combination of fluorescent-labelled Annexin 5 (Anx-F) with different Vitamin E derivatives as carriers 1 hour after topical administration.

25 Figure 4 contains images of the eye showing a time sequence of passage, using α -tocopherol Anx-F applied to the eye, the images were taken at indicated time points after topical administration.

30 Figure 5 shows the crystal structure of Annexin 5 (shown left), which is a prototype for all members of the annexin family. The highly alpha-helical core of the protein contains the calcium-binding sites, and is conserved in annexins throughout evolution.

Figure 6 shows linear schematic representations of Annexins 5, 2, 6 and 11. The N-termini are to the left and the C-termini to the right. The core of each protein is represented by the shaded grey boxes, each one of which corresponds to the well known 'annexin repeat', a

domain of approximately 70 amino-acids that is conserved both within individual annexins and also between members of the family.

Figure 7 shows an in vivo image obtained using fluorescent-labelled Annexin 11 with α -tocopherol of the same eye at 2 hours after topical administration.

Figure 8 shows the results of an assay testing the combination of a vitamin E derivative and a cell death marker.

Figure 9 shows the results of an assay testing the delivery of cargo to the posterior segment.

Figure 10 shows fluorescent-labelled Annexin with α -tocopherol in the same eye at baseline (left) and 1 hour after administration (right), with focussing in the plane in front of the retina.

15 **EXAMPLES:**

Figures 1 and 2 demonstrate that tocopherol can be used to deliver Annexin V to the eye.

Fluorescently labelled annexin V mixed with tocopherol was administered topically to the eye two hours after treatment with intravitreal staurosporine (SSP) to induce apoptosis. Cell death in the eye was measured using DARC imaging.

EXAMPLE 1: Delivery of infrared-labelled annexin V to the eye for DARC (Detection of Apoptosing Retinal Cells) Imaging.

25 Staurosporine (SSP) was administered intra-vitreally to a rat eye to induce apoptosis of retinal ganglion cells (RGC). Two hours later infrared labelled annexin V mixed with tocopherol was given topically. The eye was imaged using the DARC (Detection of Apoptosing Retinal Cells) technique¹ with a modified cSLO (confocal scanning laser ophthalmoscope) at 790 nm (Heidelberg Retina Angiograph 2, Heidelberg Engineering, Dossenheim, Germany)^{1, 2, 3}. The standard lens (15° x 15° to 30° x 30°) and the wide-field lens (55° - all degree values calibrated for the human eye) were used. Reflectance and corresponding fluorescent images with different focus settings were taken of the rat retina. To improve the signal-to-noise ratio

and to enhance image contrast, the mean image output of a series of single images (up to 100) was calculated after correction of eye movements.


5 Infrared annexin V can clearly be seen in the retina, showing apoptosing cells. Figure 2 was generated by taking a further image two hours later.

EXAMPLE 2 - Different Vitamin E derivatives used for carrier

Vitamin E is used as the generic description for all tocol and tocotrienol derivatives, with similar biological activity as α -tocopherol – the first characterized molecule (1). There are 8


10 Vitamin E isomeric molecules: the four tocopherols possess a 4',8',12'-trimethyltridecyl phytol side chain and the four tocotrienols differ by the presence of double bonds at the 3',7' and 11' positions of the side chain.

(a). Tocotrienol



20

(b). Tocopherol



30

Tocopherol / Tocotrienol	R ₁	R ₂	R ₃
α -	CH ₃	CH ₃	CH ₃
β -	CH ₃	H	CH ₃
γ -	H	CH ₃	CH ₃
δ -	H	H	CH ₃

35

The inventors have assessed all the above, and the images in figure 3 show examples of a combination of fluorescent-labelled Annexin 5 (Anx-F) with different Vitamin E derivatives as carriers 1 hour after topical administration. Note the white spots (annexin 5 positive labelling of cells) in the images confirm the passage of the combination through the cornea, 40 vitreous and onto the retina.

The graph in figure 3d shows the activity of each of the tocopherols as shown by the fluorescence corresponding to levels of annexin. PC:PS:Chol:Toc membranes containing either 1 or 10% Tocopherol.

5 The inventors have also established a time sequence of passage, as shown in figure 4, using α - tocopherol Anx-F applied to the eye with images taken at indicated time points after topical administration.

10 The inventors believe that the reason for the clarity of the image at 2.5 hours is because at this point the fluorescence in the vitreous has cleared or settled. Importantly however, activity in the retina is apparent as early as 30 minutes after topical administration.

EXAMPLE 3: Different Annexins used for carrier.

15 Since the combination of tocopherol/tocotrienol with Annexin 5 mediates trans-scleral delivery of the annexin to the retina, the question arises as to whether this effect is specific to Annexin 5 or a generic annexin property. The inventors tested this using other annexins such as Annexins 2, 6 and 11, and found that all may be used in the carrier composition (see later). The structure of Annexin 5 is shown in figure 5 (taken from Huber, R., Berendes, R., Burger, A., Schneider, M., Karshikov, A., Luecke, H. Romisch, J., Paques, E. (1992). Crystal and 20 molecular structure of human annexin V after refinement. Implications for structure, membrane binding and ion channel formation of the annexin family of proteins. J.Mol.Biol. 223:683-704) in three dimensions, and below in two dimensions along with those of annexins 2, 6 and 11 (Figure 6).

25 These annexins differ from Annexin 5 by having a slightly longer N-terminus, a duplication of the tetrad repeat, and a much longer N-terminus respectively. Since all Annexins tested may be used in the carrier composition, we attribute this generic property to the conserved 'annexin repeat', this being the only molecular determinant common to all four proteins.

30 The in vivo image in figure 7 was obtained using fluorescent-labelled Annexin 11 with α -tocopherol of the same eye at 2 hours after topical administration. The white spots clearly demonstrate that Annexin 11 may be used in the carrier composition to detect apoptosis in vivo.

EXAMPLE 4: Combination of Annexins with Vitamin E constitutes optimized carrier

The inventors have shown that it is only the combination of Annexins with the Vitamin E molecules/derivatives that is transported across the cornea following application as an eyedrop into the eye. For example, neither annexin 5 nor annexin 11 enter the eye by themselves when delivered topically. Also, as further examples, neither α -tocopherol with ovalbumin, nor α -tocopherol with dextran enters the eye. Likewise δ -tocopherol and γ -tocopherol do not enter the eye unless administered as a complex with annexin, as can be seen in figure 8.

5 Our findings also suggest that the combination of annexin with Vitamin E derivatives may be augmented and/or regulated by phosphatidylserine and cholesterol. Altering the concentrations of each of these 4 molecules greatly affects the efficacy of trans-scleral and transcorneal delivery.

10 Our findings also suggest that the combination of annexin with Vitamin E derivatives may be augmented and/or regulated by phosphatidylserine and cholesterol. Altering the concentrations of each of these 4 molecules greatly affects the efficacy of trans-scleral and transcorneal delivery.

15 **EXAMPLE 5: Delivery of cargo to the posterior of the eye.**

As shown in figure 9, it is possible to use the compositions of the invention to deliver other agents or cargo to the posterior region of the eye. Both examples illustrate an increase in the level of background fluorescence after administration, confirming the passage of the cargo to the back of the eye.

20

EXAMPLE 6: Delivery to other parts of the eye

Our studies so far have demonstrated that when an Annexin is given topically in combination with a Vitamin E derivative, the fluorescently tagged Annexin (or other fluorescent molecule) can be detected in the retina.

25

For the carrier Anx-F to reach the retina from the outside of the eye, it has to pass through the cornea, enter the aqueous humour of the anterior and posterior chambers (where it comes into contact with the iris, ciliary body, trabecular meshwork (TM) and lens) and then back into the vitreous, from where it passes to the retina.

30

The in vivo images in figure 10 show fluorescent-labelled Annexin with α -tocopherol in the same eye at baseline (left) and 1 hour after administration (right), with focussing in the plane

in front of the retina. The bright fluorescent signal is obtained due to fluorescence in the vitreous.

5 The carrier in combination with an appropriate diagnostic or therapeutic cargo can therefore be used to target any of the tissues shown above, and is thus applicable to diseases such as glaucoma, cataract, uveitis, diabetic retinopathy (DR), retinal detachment (RD) and AMD (age-related macular degeneration). We believe our carrier combination will be applied to treatments such as for AMD & DR, where currently anti-VEGF therapies are administered as an intravitreal injection.

10

References

1. Cordeiro MF, Guo L, Luong V, et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. *Proc Natl Acad Sci USA* 2004; 101: 13352-13356.
- 15 2. Guo L, Salt TE, Luong V, et al. Targeting amyloid- β in glaucoma treatment. *Proc Natl Acad Sci USA* 2007.
3. Maass A, Lundt von Leithner P, Luong V, et al. Assessment of rat and mouse RGC 20 apoptosis imaging in-vivo with different scanning laser ophthalmoscopes. *Curr Eye Res* 2007; [accepted for publication].

Claims

1. A pharmaceutical composition comprising Vitamin E derivative and a cell death marker.
5
2. A pharmaceutical composition according to claim 1, wherein the cell death marker is an annexin.
- 10 3. A pharmaceutical composition according to claim 2, wherein the annexin is annexin V.
4. A pharmaceutical composition according to any preceding claim, wherein the Vitamin E derivative is a tocopherol or a derivative thereof.
15
5. A pharmaceutical composition according to claim 4, wherein the tocopherol is D- α -tocopherylsuccinate esterified to polyethyleneglycol 1000.
6. Use of a Vitamin E derivative as a carrier for enhancing delivery of at least one agent to the posterior segment of the eye.
20
7. Use according to claim 6 wherein the agent comprises a cell death marker.
8. Use according to claim 6 or claim 7, wherein the Vitamin E derivative is a tocopherol, especially D- α -tocopherylsuccinate esterified to polyethyleneglycol 1000.
25
9. Use according to any one of claims 6 to 8, wherein the Vitamin E derivative is formulated for topical delivery.
- 30 10. Use according to any of claims 6 to 9, wherein the carrier is for enhancing delivery to the retina.

11. A method of delivery of at least one agent to the posterior segment of the eye, comprising delivering the agent to the eye, in combination with a Vitamin E derivative.

5 12. A method according to claim 11, wherein the agent and Vitamin E derivative are delivered topically.

13. A method according to claim 11 or 12, wherein the Vitamin E derivative is tocopherol, especially D- α -tocopherylsuccinate esterified to polyethyleneglycol 1000.

10 14. A method according to any of claims 11 to 13, wherein the method is for delivering an agent to the retina.

15 15. A method according to any of claims 11 to 14, wherein the agent is a cell death marker.

16. A method according to claim 15, comprising delivering a second agent.

Results of topical Annexin

Annexin IR Dosage = 125 μ g carrier
SSP 30 mins




Figure 1




Figure 2a





Figure 2b

Figure 3a

 α - tocopherol




Figure 3b

Figure 3c

γ - tocopherol





Figure 3d






Figure 4




Figure 5




Figure 6







Figure 7




α -tocopherol with
(left) and without
(right) Anx-F.




α - tocopherol with
fluorescein sodium
with annexin 5 (left)
and without annexin
5 (right)

Notice high level of fluorescence on annexin 5 (left) eye.

Figure 8




δ - tocopherol with (left) and without Anx-F (right)




γ - tocopherol with (left) and without Anx-F (right)

Figure 8 continued



Fluorescein Sodium : Images taken at baseline (left) and 2hrs after administration with combination of annexin & vitamine E derivative.



YoPro: Images taken at baseline (left) and 2hrs after administration with combination of annexin & vitamine E derivative.

Figure 9




Figure 10